Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Label indication IMFINZI is a programmed death-ligand 1 (PD-L1) blocking antibody indicated: • in combination with platinum-containing chemotherapy as neoadjuvant treatment, followed by IMFINZI continued as a single agent as adjuvant treatment after surgery, for the treatment of adult patients with resectable (tumors ≥ 4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR)… FDA label
Also known as Imfinzi
Durvalumab · 1 trial · 1 indication
The number of dose limiting toxicities will be counted for each cohort.
| Arm | Type | Description |
|---|---|---|
| Copanlisib (30-60mg iv) | EXPERIMENTAL | Patients in the group will receive Durvalumab at 10mg/kg (IV infusion on days 1 and 15, q28 days or 1500mg day 1 q28d). They will also receive Copanlisib ranging from 30mg to 60mg (IV infusion on days 1 and 15, q 28 days). |
| Name | Type | Description |
|---|---|---|
| Durvalumab | DRUG | Durvalumab will be delivered at 10mg/kg via IV infusion at days 1 and 15 every 28 days or 1500 mg on D1, q4w. |
| Copanlisib | DRUG | Copanlisib will be delivered at various doses (30-60mg/kg) via IV infusion at days 1 and 15 every 28 days. |
Inclusion Criteria: * Histologically confirmed NSCLC (e.g., adenocarcinoma, squamous cell) deemed unresectable or inoperable who have received concurrent chemoradiation. * Durvalumab will be started as consolidation therapy * Have at least one measurable lesion. * ECOG performance status ≤2. * Adeq...
Top 20 of 90 competitors